Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models
Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …
challenges facing cardiovascular medicine today. Despite being the most common form of …
Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure
Tissue-tissue communication by endocrine factors is a vital mechanism for physiologic
homeostasis. A systems genetics analysis of transcriptomic and functional data from a cohort …
homeostasis. A systems genetics analysis of transcriptomic and functional data from a cohort …
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models
Heart failure (HF) with preserved ejection fraction (HFpEF) is a multifactorial disease
accounting for a large and increasing proportion of all clinical HF presentations. As a clinical …
accounting for a large and increasing proportion of all clinical HF presentations. As a clinical …
[HTML][HTML] SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
I Tuleta, NG Frangogiannis - Advanced drug delivery reviews, 2021 - Elsevier
In patients with diabetes, myocardial fibrosis may contribute to the pathogenesis of heart
failure and arrhythmogenesis, increasing ventricular stiffness and delaying conduction …
failure and arrhythmogenesis, increasing ventricular stiffness and delaying conduction …
Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity with
complex pathophysiology and manifestations. Phenomapping is the process of applying …
complex pathophysiology and manifestations. Phenomapping is the process of applying …
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Obesity-related heart failure with preserved ejection fraction (HFpEF) has become a well-
recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may …
recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may …
DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters
NM Stege, TR Eijgenraam… - Circulation …, 2023 - Am Heart Assoc
BACKGROUND: The p. Arg14del variant of the PLN (phospholamban) gene causes
cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear …
cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear …
Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs?
L Cornuault, P Rouault, C Duplàa, T Couffinhal… - Frontiers in …, 2022 - frontiersin.org
Heart failure with preserved ejection fraction (HFpEF) has been recognized as the greatest
single unmet need in cardiovascular medicine. Indeed, the morbi-mortality of HFpEF is high …
single unmet need in cardiovascular medicine. Indeed, the morbi-mortality of HFpEF is high …